Dr. Harvinder Singh

Dr Harvinder Singh joined ICMR-NIHR, Jodhpur as a Scientist-B in February 2026. He holds a PhD in Pharmacology from PGIMER, Chandigarh, and completed his undergraduate and postgraduate studies in Microbiology at MGSU, Bikaner. Prior to his current role, he served as a Research Associate at PGIMER, Chandigarh, for two years.

Dr Singh is a recipient of the prestigious Young Scientist Travel Award from DST-SERB and was honoured with two Annual Research Day Awards in 2025 for his contributions to innovation and published research. He has qualified for several prominent national fellowships, including CSIR-UGC-JRF, ICMR-JRF, GATE (Life Sciences), ICAR-NET (Microbiology), and the FSSAI-JAE (FIFA) fellowship. Currently, Dr Singh serves as the In-charge of the Microbiology Laboratory at ICMR-NIHR.

Under his leadership, the BioIT Lab was established within the Department of Microbiology. The facility specializes in microbiological testing, including Antimicrobial Susceptibility Testing (AST), alongside advanced drug discovery focusing on enzyme inhibitors and ion-channel blockers. The lab’s mandate emphasizes interdisciplinary research, bridging the gap between Microbiology and Pharmacology to drive drug discovery initiatives.

Notably, this laboratory is the only facility of its kind in Western Rajasthan, significantly strengthening the research capacity of ICMR-NIHR, Jodhpur, India.

Specialisations: Data science and Genomics data science, School of Public Health, The Johns Hopkins University, USA

PhD- Pharmacology, PGIMER, Chandigarh

MSc -Microbiology, Maharaja Ganga Singh University, Bikaner

BSc- Microbiology, Maharaja Ganga Singh University, Bikaner

Computational Structural biology: Protein modelling, MD simulations, Drug discovery/development: virtual screening and Gmx_qk tool, Microbiology: AST, molecular diagnostics, and enzyme assay development.

Focus: Workflow automations for antimicrobial resistance and translational pharmacology at ICMR-NIHR, Jodhpur

1. Singh H, Raja A, Chauhan A, Jain A, Prakash A, Bhatia A, et al. Unlocking the Therapeutic Potential: Sitagliptin’s Multifaceted Approach in Drug-Resistant Epilepsy through a Novel Mechanism Inhibiting Protein Kinase C-γ and a Long-Term Potentiation Pathway. ACS Pharmacol Transl Sci [Internet]. 2024 May 13; Available from: https://doi.org/10.1021/acsptsci.4c00073, IF: 6.0

2. Singh H, Raja A, Shekhar N, Chauhan A, Prakash A, Avti P, Medhi B. Computational attributes of protein kinase-C gamma C2-domain & virtual screening for small molecules: elucidation from meta-dynamics simulations & free-energy calculations. Journal of Biomolecular Structure and Dynamics. 2022 May 14:1-2, IF:5.2

3. Singh H, Raja A, Prakash A, Medhi B. Gmx_qk: An automated protein/protein–ligand complex simulation workflow bridged to MM/PBSA, based on GROMACS and Zenity-Dependent GUI for beginners in MD simulation study. Journal of Chemical Information and Modeling. 2023 Apr 20;63(9):2603-8. IF: 5.6

4. Raja A, Shekhar N, Singh H, Prakash A, Medhi B. In-silico discovery of dual active molecule to restore synaptic wiring against autism spectrum disorder via HDAC2 and H3R inhibition. PLoS One. 2022 Jul 25;17(7):e0268139. doi: 10.1371/journal.pone.0268139. PMID: 35877665; PMCID: PMC9312418 IF:3.76

5. Shekhar N, Sarma P, Prajapat M, Avti P, Kaur H, Raja A, Singh H, Bhattacharya A, Sharma S, Kumar S, Prakash A. In silico structure-based repositioning of approved drugs for spike glycoprotein S2 domain fusion peptide of SARS-CoV-2: rationale from molecular dynamics and binding free energy calculations. Msystems. 2020 Sep 22;5(5):e00382-20. IF: 7.53

6. Kaur B, Singh H, Choudhary G, Prakash A, Medhi B, Chatterjee D, Saini UC, Kaur J, Verma I, Sharma S. Natural angiotensin II type 1 receptor inhibitors: Virtual screening and in vitro evaluation of beta-1, 2, 3, 4, 6-penta-O-galloyl-d-glucopyranose, icarrin, and sesamin for osteoarthritis therapy. International Journal of Biological Macromolecules. 2025 Mar 25:142184. IF: 7.7

7. Ghani A, Singh H, Kumar H, Vaiphei K. MicroRNA expression signature in gastrointestinal stromal tumour & their molecular & histological features. The Indian Journal of Medical Research. 2024 Sep 30;160(1):118. IF: 2.7

8. Kumar S, Singh H, Prajapat M, Sarma P, Bhattacharyya A, Kaur H, Kaur G, Shekhar N, Kaushal K, Kumari K, Bansal S. Structural-Based Virtual Screening of FDA-Approved Drugs Repository for NSP16 Inhibitors, Essential for SARS-COV-2 Invasion Into Host Cells: Elucidation From MM/PBSA Calculation. Bioinformatics and Biology Insights. 2023 Jul;17:11779322231171777. IF: 2.3

9. Kaur G, Prajapat M, Singh H, Sarma P, Bhadada SK, Shekhar N, Sharma S, Sinha S, Kumar S, Prakash A, Medhi B. Investigating the novel-binding site of RPA2 on Menin and predicting the effect of point mutation of Menin through protein–protein interactions. Scientific Reports. 2023 Jun 8;13(1):9337. IF: 3.8

10. Chauhan A, Singh J, Sangwan N, Singh H, Prakash A, Medhi B, Avti PK. Designing the 5HT2BR structure and its modulation as a therapeutic target for repurposing approach in Drug-resistant epilepsy. Epilepsy Research. 2023 May 30:107168 IF: 2.2

11. Prajapat M, Singh H, Chaudhary G, et al. A Novel Inhibitor of DKK1/LRP6 Interactions Against the Alzheimer Disease: An Insilco Approach. Bioinformatics and Biology Insights. 2023;17. doi:10.1177/11779322231183762. IF: 2.3

12. Badal R, Kaur B, Singh H, Sharma P, Yadav P, Mahapatra A, Ghildiyal S, Patel AK, Kumar L, Sharma B, Prajapati PK. Saraswata Ghrita mitigates AlCl₃-and D-galactose–induced cognitive deficits in a murine Alzheimer’s-like model: In silico and in vivo insights. Brain Research Bulletin. 2026 Jan 21:111742. IF: 3.7

13. Gupta T, Devi V, Rao A, Bharti R, Singh H, Kumar M, Kaundal T. Molecular forensics: RNA degradation as a marker for postmortem interval determination. International Journal of Legal Medicine. 2026 Jan 9:1-3. IF: 2.3

14. Bhat S, Basak P, Verma S, Siddiqui K, Dutta P, Das L, Singh H, Bhadada S, Sachdeva N. Type 2 diabetes compromises SARS-CoV-2-specific immunological memory following ChAdOx1 nCoV-19 vaccination. Vaccine. 2025 Aug 30;62:127604. IF: 3.5

15. Jain A, Dhir N, Prabha PK, Raja A, Sharma AR, Kaundal T, Charan S, Singh H, Singla R, Malik D, Bhatia A. Restoring brain function in autism: GSK3β inhibition by 6-bromoindirubin-3′-oxime reverses valproic acid-induced neuropathology. ACS Chemical Neuroscience. 2025 Jun 20;16(13):2395-419. IF: 3.9

16. Prakash A, Singh H, Sarma P, Bhattacharyya A, Dhibar DP, Balaini N, Shree R, Goyal M, Modi M, Medhi B. nCoV-2019 infection induced neurological outcome and manifestation, linking its historical ancestor SARS-CoV and MERS-CoV: a systematic review and meta-analysis. Scientific reports. 2021 Jun 18;11(1):1-5 IF: 4.9

17. Prakash A, Singh H, Kaur H, Semwal A, Sarma P, Bhattacharyya A, Dhibar DP, Medhi B. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian Journal of Pharmacology. 2020 Sep;52(5):414 IF: 1.20

18. Singh H, Kaur H, Medhi B. Novel therapeutic approaches toward Hantaan virus and its clinical features’ similarity with COVID-19. Indian Journal of Pharmacology. 2020 Sep;52(5):347. IF: 1.20

19. Choudhary G, Prajapat M, Kaur G, Singh H, Mahendiratta S, Prakash A, Medhi B. Integrated in-silico and in-vitro assessments of HDAC6 inhibitor efficacy in mitigating amyloid beta pathology in Alzheimer’s disease. Journal of Biomolecular Structure and Dynamics. 2024 Dec 11;42(18):9720-30. IF: 2.7

20. Jain A, Dhir N, Singh H, Sharma AR, Medhi B, Prakash A. Disrupting maternal behavior and inducing cannibalism due to valproic acid: An unexplored insight. Basic and Clinical Neuroscience. 2024 Mar 1;15(2):261. IF: 1.0

21. Kumaravel J, Singh H, Kaur S, Prakash A, Medhi B. Peptides and peptidomimetics as a therapeutic candidate for the treatment of COVID-19: A brief review. Indian Journal of Pharmacology. 2023 Jan 1;55(1):53-8. IF: 1.4

22. Kumar S, Sarma P, Kaur H, Prajapat M, Bhattacharyya A, Avti P, Sehkhar N, Kaur H, Bansal S, Mahendiratta S, Mahalmani VM. Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review. Tissue & Cell. 2021 Jan 26;70:101497. IF: 2.7

Book Chapters

1. Kaur G, Singh RS, Singh A, Singh H, Sinha S, Medhi B. Translational Epidemiology in Cancer Research: The Less Travelled Path. InBiomedical Translational Research: From Disease Diagnosis to Treatment 2022 Jun 15 (pp. 349-366). Singapore: Springer Nature Singapore.

2. Raja A, Mahendiratta S, Singh H, Shekhar N, Prakash A, Medhi B. Nanoparticles in Chronic Respiratory Diseases. InAdvanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases 2022 Mar 24 (pp. 143-170). Singapore: Springer Singapore.

3. Bhandari PR. Textbook of pharmacology. Thieme; 2022 Sep 22. (CNS Stimulants and Drugs of Abuse)

4. Singh H, Singh P, Chaudhary G, Singh H. Protein Structure Modeling and Refinement. Encyclopedia of Bioinformatics and Computational Biology. 2025;612–29.

5. Singh H, Choudhary G, Siddiqui H, Singh P, Singh L, Singh S, et al. AI in biomolecular structural data analysis. Progress in Molecular Biology and Translational Science. 2026